To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
82 Current news of High-Tech Gründerfonds Managementrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Products tailored towards the Life Science industry
As a pioneer in education technology, Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the DeepTraining approach, implemented ...
HepaRegeniX secures Series B Financing
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models. HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases announced the closing of its ...
Biograil ApS, an innovative biotechnology company developing a unique oral device for delivery of biologics that would otherwise be injected, announced the closing of a seed funding of 3 Million Euro (with potential to expand to 5 Million Euro). The investor Syndicate was led by the experienced ...
The Munich-based Cunesoft GmbH, an provider of cloud-based intelligent regulatory data management software and services for the life sciences industry, announced that it has been acquired by Phlexglobal from current investors including Bayern Kapital, High-Tech Gründerfonds and ...
Over 5 Million Euros For Lindis Blood Care
As is standard during tumor surgeries, when large volumes of blood are lost, donor blood is given to the patient. Worldwide, this is the case for more than half a million tumor surgeries annually. This procedure can result in many serious side effects and increased tumor recurrence rates. ...
The goal is to develop and commercialize novel, cost-effective vaccines for animal health
The Verovaccines GmbH has signed the first cooperation agreement with a Japanese pharmaceutical partner for the joint development of an animal vaccine. This cooperation documents a significant step forward in the company’s development and the clear interest of market participants in vaccines ...
Ark-Biodiversity and HTGF have completed the first joint financing round
Ark-Biodiversity is the newest foundation of the serial entrepreneur Alexander Olek. The 50-year-old father of four children says: “I don’t believe in the survival of humanity without biodiversity; and I do not believe in the conservation of biodiversity, unless our societies find joint ...
Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...
Vacis raises capital from Brightlands Venture Partners, HTGF, LIOF and RVO
Every year, an estimated 300.000 hemodialysis patients worldwide die as they run out of medical alternatives. One of the main reasons for these deaths is failure of the vascular access site, the blood vessel where blood is removed, filtered and returned to the body during dialysis. To solve this ...
Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and ...